Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To Purchase An Aggregate Of Up To 39,473,688 Of Lineage's Common Shares At A Combined Purchase Price Of $0.76 Per Common Share And Accompanying Common Warrant
lineage cell therapeutics与特定的机构投资者和Broadwood Partners, L.P.签订了最终协议，以购买和销售高达39,473,688股lineage普通股和相应的认股权证，购买价格为每股0.76美元，并附带普通股认股权证
$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants
3,000万美元的初始费用，全额行使临床里程碑关联普通股认股权可获得高达3,600万美元的综合毛收益
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. ("Broadwood"), an affiliate of Neal Bradsher, a member of Lineage's board of directors, for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage's common shares at a combined purchase price of $0.76 per common share and accompanying common warrant, in a registered direct offering. Each common warrant will be exercisable for one common share at an exercise price of $0.91 per common share and will be exercisable commencing six months following their date of issuance and will expire on the earlier of (a) the three-year anniversary of the initial exercise date, and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to the initial exercise date of the common warrants, the 90th day following the initial exercise date. However, the common warrants that may be issued to Broadwood will not be exercisable until the later of (i) their date of issuance, which will be the date shareholder approval is obtained, and (ii) the six-month anniversary of the date of issuance of the common warrants to the unaffiliated institutional investors in the offering.
生物技术公司lineage cell therapeutics, Inc. (NYSE美国交易所和TASE：LCTX)是一家临床阶段的公司，致力于为未满足的医疗需求开发异基因细胞疗法，今日宣布与特定以医疗为重点的机构投资者和Broadwood Partners, L.P.（“Broadwood”）达成最终协议，由Neal Bradsher的关联公司Broadwood购买及出售高达39，473，688股lineage普通股和相应认股权证（“普通认股权证”），购买价格为每股0.76美元，并附带普通股认股权证，在一次公开直接发行。每个普通认股权证可按行权价格0.91美元行使一股普通股，自发行之日起六个月后行使，于最早的一下日期到期：(a)初始行权日期三周年日期，和(b)正面向普腾（又名RG6501）推进至多中心2或3期临床试验，并包括对照组或比较组的公开意图的日期，或者如果该公开意图日期早于普通认股权证的初始行权日期，则是普通认股权证的初始行权日期之后第90天。然而，可能发行给Broadwood的普通认股权证直至后者行使，即(i) 股东批准日的发行日期和(ii）发行给发行的非关联机构投资者普通认股权证之日起六个月周年日期之后，才可行使。
H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering.
H.C. Wainwright & Co. 作为本次发行的独家配售代理。
